HHS Regulatory Agenda Omits Drug Pricing Actions – Unless OTC Switches Still Count
Executive Summary
HHS’ 'statement of regulatory priorities' for 2018 does not even offer lip service to idea of addressing Rx costs. It does, however, suggest plans to move forward with an effort to increase OTC switches – which was an Obama era idea to lower drug costs.
You may also be interested in...
Rulemaking For OTC Switch Process Changes Pushed To 2019
Target date moved from August 2018 to February 2019 for publishing an NPRM for allowing currently Rx drug ingredients to be available nonprescription under conditions of safe use. US HHS annual spring update on regulatory priorities for FDA and its other agencies also pushes back target dates for other OTC drug NPRMs, including FDA's long-delayed finalization of several monographs including sunscreen ingredients.
Rulemaking For OTC Switch Process Changes Pushed To 2019
Target date moved from August 2018 to February 2019 for publishing an NPRM for allowing currently Rx drug ingredients to be available nonprescription under conditions of safe use. US HHS annual spring update on regulatory priorities for FDA and its other agencies also pushes back target dates for other OTC drug NPRMs, including FDA's long-delayed finalization of several monographs including sunscreen ingredients.
340B Penny Pricing, Civil Monetary Penalty Revisions On Deck In Proposed Rule
Proposed rule will revisit controversial provisions in the January 340B final rule to address manufacturer concerns about the US discount program.